Introduction
Most regulatory affairs conversations about drug pathways gravitate toward NDAs, ANDAs, and BLAs. There's a quieter corner of the industry that runs on a different set of rules entirely: the over-the-counter (OTC) monograph system, which governs a large share of the nonprescription products on pharmacy shelves — pain relievers, antacids, sunscreens, antiperspirants, dandruff shampoos, and more. For decades this system moved through slow, cumbersome notice-and-comment rulemaking. In 2020, the CARES Act rewrote the process, and that rewrite has quietly created a specialized, growing lane of regulatory affairs work that doesn't get nearly the attention it deserves.
If you've spent your career on prescription drug submissions, the monograph world can look unfamiliar at first. But for regulatory professionals who understand it, it's becoming a genuinely useful specialization — one with real hiring demand and comparatively little competition for experienced talent.
What the OTC Monograph System Actually Is
Under the monograph system, an OTC drug doesn't need its own individual marketing approval the way a prescription product does. Instead, entire categories of active ingredients, uses, and labeling are governed by a monograph — essentially a standardized rulebook for that drug category. If a company's product conforms to the applicable monograph's active ingredients, dosage, and labeling requirements, it can be marketed without a product-specific FDA approval.
That sounds simpler than the NDA pathway, and in some ways it is. But conformance is its own discipline. A regulatory professional working in this space needs to know a monograph's requirements as well as an NDA reviewer knows an approved labeling document, because the margin for interpretation is real and the consequences of getting it wrong — a warning letter, an import refusal, a product seizure — are not trivial.
Why the CARES Act Reform Matters
Before 2020, updating a monograph required formal rulemaking, a process so slow that some monographs sat in proposed (rather than final) status for decades, creating persistent regulatory ambiguity. The CARES Act replaced that rulemaking process with an administrative order process, letting FDA issue orders to establish, amend, or revoke monograph conditions without the full rulemaking cycle. It also created a user fee program for OTC monograph drug facilities and products, funding dedicated FDA review resources, and it gave industry a mechanism to request changes — including safety-related labeling changes and innovation-related changes to expand permitted uses — through structured administrative order requests.
The practical effect is that the monograph system, once nearly static, is now an active regulatory environment with orders, meetings, and administrative dockets to track. That shift is what created the hiring niche: the work of monitoring, interpreting, and acting on this now-moving target requires people who didn't previously need to exist in this role.
What This Work Actually Involves
Day to day, a regulatory professional focused on OTC monograph products spends time on things that look different from prescription-drug regulatory work. Label conformance review against monograph-specific requirements is constant, since OTC labeling is tightly prescribed and consumer-facing claims carry real enforcement risk if they drift from what the monograph permits. Tracking administrative orders and associated dockets matters because monograph conditions can change, and a company's product formulation or claims may need updating in response. Facility and product registration under the OTC monograph user fee framework is its own administrative workstream, distinct from prescription drug facility registration. And for companies seeking to innovate within a monograph — a new combination, a new use, a new dosage form — there's now a formal administrative order request pathway, which requires building a technical and safety case in a format FDA didn't previously have a defined channel to receive.
None of this maps cleanly onto NDA or ANDA experience. It's closer to a hybrid of regulatory affairs, labeling, and regulatory intelligence, with its own vocabulary and its own document types.
Safety labeling changes deserve a section of their own, because they're one of the more urgent and higher-stakes workstreams in this niche. When new safety information emerges about an OTC active ingredient — a signal from adverse event reporting, a finding from post-market surveillance, or new data on a drug interaction — a company may need to move quickly to update labeling for every product built on that monograph condition. That work involves assessing whether a proposed labeling change is mandatory or voluntary, understanding how quickly FDA expects implementation, and coordinating across every affected product line and packaging configuration a company markets, which can be a surprisingly large operational lift for a company with a broad OTC portfolio.
Who's Hiring for This
The clearest demand comes from consumer health companies — both the large pharma-adjacent consumer health divisions and the standalone OTC and personal care companies that make up a meaningful share of the drugstore aisle. Private-label and contract manufacturers supplying retailer store brands need this expertise too, since they're often managing conformance across many product lines simultaneously. Regulatory consultancies have built out monograph-specific service lines to serve smaller OTC brands that can't justify a full-time in-house specialist. And companies pursuing Rx-to-OTC switches — moving a prescription product to nonprescription status — increasingly need people who understand both the switch application process and the monograph environment the product will eventually live in.
Skills That Set Candidates Apart
Experience with FDA's OTC monograph administrative order process and its associated dockets is the clearest differentiator, since relatively few regulatory professionals have hands-on exposure to it. Familiarity with label comprehension and consumer research requirements is valuable, because OTC labeling changes often require supporting studies that prescription labeling doesn't. Understanding of the OTC monograph user fee facility and product registration requirements rounds this out, since it's a compliance obligation distinct from anything in the prescription drug world. None of this requires a pharmacy or toxicology degree specifically — a general regulatory affairs or life sciences background works fine — but it does require deliberately building familiarity with a system most regulatory training programs barely mention.
How to Position Yourself If You're Interested
The most direct way in is to start reading FDA's OTC monograph administrative order dockets and safety-related orders directly; they're public, and following a handful of them for a few months builds real fluency faster than most training courses would. If your current role touches consumer-facing labeling in any capacity, highlight that experience specifically — label conformance skills transfer well into this niche. The Consumer Healthcare Products Association is the natural professional home for this specialization and a good source of both continuing education and networking. And if you're already inside a company that makes any OTC products, volunteering for monograph-related projects is often the fastest way to build the experience that makes you hireable for a dedicated role elsewhere.
Common Missteps for Newcomers to the Niche
Regulatory professionals moving into monograph work from a prescription-drug background sometimes underestimate how much the compliance mindset shifts. There's no single review team approving a specific product; instead, the company itself carries the ongoing responsibility to determine and defend conformance, which means the burden of proof lives with the regulatory team rather than with an agency reviewer signing off once. It's also easy to underestimate how much monograph work intersects with marketing and claims review, since OTC products live or die commercially on their labeling claims, and a regulatory professional in this niche often ends up as the primary check on whether a proposed consumer-facing claim is actually permitted under the applicable monograph. Finally, newcomers sometimes assume the administrative order process moves as slowly as the old rulemaking system it replaced; it doesn't always, and treating an active docket as a low-priority background task is a good way to miss a deadline that has real commercial consequences.
How This Compares to Adjacent Specializations
It's worth distinguishing monograph work from two specializations it sometimes gets confused with. Dietary supplement and nutraceutical regulatory affairs operates under a different framework entirely — supplements are regulated as food products with their own labeling and claims rules, not as OTC drugs subject to a monograph — and while the two fields share some consumer-labeling instincts, the underlying legal frameworks and the agencies' review posture are quite different. Rx-to-OTC switch work is closer, since a successfully switched product often ends up living under a monograph once it's on the market, but the switch application itself is a distinct, product-specific regulatory process that resembles standard prescription drug work far more than ongoing monograph conformance does. Regulatory professionals sometimes move between these three areas over a career, but they're worth naming separately and accurately, both because interviewers in this space tend to notice imprecise terminology and because each area rewards a somewhat different skill set.
There's also a useful distinction to draw with cosmetics regulatory work, since the two categories sit right next to each other on a drugstore shelf but answer to different legal definitions. A product is regulated as an OTC drug, rather than a cosmetic, based on the claims made about it and its intended use, not simply its ingredient list or its physical form — a moisturizer with sunscreen claims is a drug product subject to the sunscreen monograph, while a moisturizer without those claims is a cosmetic. Regulatory professionals who understand where that line falls, and how a marketing team's proposed claim can accidentally push a product across it, bring real value to companies with combined cosmetic and OTC portfolios.
Conclusion
The OTC monograph system spent decades as a regulatory backwater, and hiring reflected that. The 2020 reform changed the underlying mechanics enough that the system now requires active, ongoing regulatory attention — and the people who can provide that attention are still relatively scarce. For regulatory professionals looking for a specialization with real, underserved demand, this is worth a closer look.